Last updated: September 9, 2026
Dolutegravir sodium is the active pharmaceutical ingredient in Tivicay, Dovato, Triumeq and several global fixed-dose antiretroviral combinations. Its commercial position remains strong because of high virologic efficacy, once-daily dosing, a high resistance barrier and broad use in first-line HIV treatment. The main financial risk is not biosimilar substitution but generic erosion after core compound and formulation protections expire, combined with migration toward newer two-drug and long-acting regimens.
ViiV Healthcare controls the principal branded dolutegravir portfolio. GSK owns a majority interest in ViiV, with Pfizer and Shionogi as minority shareholders. Dolutegravir-containing products generate multibillion-pound annual sales across developed and emerging markets, although ViiV reports most figures by brand rather than by active ingredient.
What drugs contain dolutegravir sodium?
Dolutegravir sodium is marketed as a single agent and in fixed-dose combinations.
| Product |
Active ingredients |
Developer or marketer |
Primary use |
| Tivicay |
Dolutegravir sodium |
ViiV Healthcare |
HIV-1 treatment with other antiretrovirals |
| Dovato |
Dolutegravir and lamivudine |
ViiV Healthcare |
Complete two-drug HIV-1 regimen |
| Triumeq |
Dolutegravir, abacavir and lamivudine |
ViiV Healthcare |
Complete three-drug HIV-1 regimen |
| Juluca |
Dolutegravir and rilpivirine |
ViiV Healthcare |
Complete two-drug regimen for virologically suppressed adults |
| Triumeq PD |
Dolutegravir, abacavir and lamivudine |
ViiV Healthcare |
Pediatric HIV treatment |
| TLD |
Tenofovir disoproxil fumarate, lamivudine and dolutegravir |
Multiple generic manufacturers |
Global HIV treatment, mainly lower- and middle-income markets |
The U.S. Food and Drug Administration approved Tivicay in August 2013 and Dovato in April 2019. Juluca was approved in November 2017, while Triumeq received U.S. approval in August 2014. FDA approval established dolutegravir as a central component of modern integrase inhibitor-based therapy. (FDA, 2013, 2014, 2017, 2019)
How large is the dolutegravir sodium market?
The commercial market has two distinct segments: branded sales in high-income countries and volume-driven generic supply in lower-income markets.
Branded market
ViiV’s dolutegravir portfolio has historically included three of the company’s largest commercial products:
- Tivicay, the core single-agent brand.
- Triumeq, the earlier three-drug combination.
- Dovato, the principal growth product within the two-drug regimen segment.
Dovato has partially offset Triumeq erosion as clinicians move away from abacavir-containing regimens and adopt two-drug maintenance or initial-treatment strategies. Tivicay remains important because it is used with multiple backbone regimens and is included in pediatric and treatment-experienced protocols.
ViiV reported total 2023 sales of approximately £7.9 billion across its HIV portfolio. Dolutegravir-containing brands represented a substantial portion of those sales, but ViiV does not report a consolidated global figure for the active ingredient itself. Product-level performance is affected by country pricing, tender contracts, combination-product accounting and royalty arrangements. (ViiV Healthcare, 2024)
Generic and public-sector market
The global generic market is substantially larger by patient volume than the branded market. The World Health Organization recommends dolutegravir-based regimens as preferred first-line treatment for most people with HIV, subject to clinical considerations. TLD has become a standard public-sector regimen because it combines efficacy, tolerability, low pill burden and relatively low manufacturing cost. (World Health Organization, 2021)
Medicines Patent Pool licensing enabled multiple manufacturers to develop and supply generic dolutegravir combinations in designated low- and middle-income countries. Suppliers have included Aurobindo, Cipla, Mylan, Hetero and other antiretroviral manufacturers under country-specific regulatory and licensing arrangements. (Medicines Patent Pool, 2014)
When does dolutegravir lose U.S. market exclusivity?
The key U.S. commercial date is the expiration of the principal compound patent and related listed patents, rather than the expiration of FDA regulatory exclusivity.
| Exclusivity event |
Approximate timing |
Commercial effect |
| FDA new chemical entity exclusivity for Tivicay |
August 2018 |
Blocked certain abbreviated applications for five years |
| Tivicay pediatric exclusivity |
Added six months to applicable qualifying patents or exclusivity |
Extended relevant protection after pediatric studies |
| Core dolutegravir compound patent |
Approximately 2027, subject to patent-term adjustment and extension |
Primary barrier to U.S. generic entry |
| Later formulation and combination patents |
Generally extend into the late 2020s or early 2030s for specific claims |
May restrict particular products, not necessarily all dolutegravir tablets |
| Dovato and Juluca regulatory exclusivity |
Expired or expires later than Tivicay’s NCE period |
Protects products separately from the underlying molecule |
The core U.S. compound patent is commonly identified as U.S. Patent No. 8,129,385, assigned to Shionogi and licensed to ViiV-related entities. Public patent records associate the patent with dolutegravir-related compounds and an expiration date in the late 2020s after patent-term adjustments. Related patents may cover crystalline forms, pharmaceutical compositions, treatment methods and combinations. (U.S. Patent and Trademark Office, 2024)
A generic manufacturer may challenge one or more Orange Book patents before the full estate expires. A listed patent’s expiration does not automatically prevent an ANDA filing, because an applicant can file a Paragraph IV certification or pursue a section viii carve-out for non-patented uses.
What is the Orange Book status of Tivicay and dolutegravir products?
Tivicay is listed in the FDA Orange Book as a prescription small-molecule drug. Orange Book protection is product-specific. The listing does not automatically cover every dolutegravir product, every salt form, or every fixed-dose combination.
Relevant patent categories include:
- Compound patents covering dolutegravir chemical structures.
- Composition patents covering tablets or pharmaceutical formulations.
- Crystalline-form or solid-state patents.
- Method-of-use patents covering HIV treatment regimens.
- Combination patents covering dolutegravir with lamivudine, abacavir, rilpivirine or other antiretrovirals.
Dovato, Triumeq and Juluca have separate regulatory applications and may have separate Orange Book listings. A generic applicant seeking approval for dolutegravir tablets could avoid certain combination-product patents if the proposed labeling excludes the protected use. A product seeking substitution for a complete regimen faces additional formulation and combination claims.
Which companies are challenging dolutegravir patents?
Generic competition already exists in many markets through voluntary licensing, public-sector procurement and national patent-law pathways. The U.S. and European commercial markets are different.
Major potential competitors include:
- Teva Pharmaceutical Industries.
- Viatris.
- Aurobindo Pharma.
- Cipla.
- Hetero.
- Laurus Labs.
- Sun Pharmaceutical Industries.
- Generic manufacturers filing abbreviated applications in the United States or Europe.
A publicly reported Paragraph IV challenge can trigger a 30-month stay if the patent owner files suit within the statutory period. Publicly available litigation activity has not established a broad U.S. generic launch before the core late-2020s patent window. Product-by-product court records and Orange Book certifications remain decisive because a challenge to Tivicay does not necessarily challenge Dovato, Triumeq or Juluca.
What patents protect dolutegravir sodium?
The main protection layers are summarized below.
| Protection layer |
Representative scope |
Strategic value |
| Core compound |
Dolutegravir chemical entities and salts |
Broadest barrier to single-agent generic entry |
| Pharmaceutical composition |
Tablet formulation and dosage forms |
Can delay or narrow substitutable products |
| Solid-state protection |
Crystalline or polymorphic forms |
May complicate API and finished-dose development |
| Treatment methods |
HIV treatment using dolutegravir |
Relevant where labeling includes protected indications |
| Fixed-dose combinations |
Dolutegravir with lamivudine, abacavir or rilpivirine |
Protects combination products independently |
| Pediatric formulations |
Dispersible tablets and pediatric dosing |
Supports lifecycle management and pediatric exclusivity |
Patent strength is highest where compound claims remain enforceable and where a proposed generic must use the protected active form or formulation. Method-of-use patents are weaker against skinny-label products, while formulation patents are vulnerable if a generic can use a non-infringing process or dosage form.
How strong is the dolutegravir patent estate?
The estate is commercially strong but structurally uneven.
The core compound patent provides the most valuable protection for Tivicay. Combination products have separate commercial defenses, but those defenses do not create an indefinite barrier to generic dolutegravir. A successful generic can target the single-agent product first, then pursue fixed-dose combinations through separate applications.
Strengths include:
- A clinically important molecule with broad treatment use.
- Multiple branded products built around the same active ingredient.
- Combination and formulation patents extending beyond the basic NCE exclusivity period.
- High switching costs for patients stabilized on branded complete regimens.
- Regulatory and manufacturing complexity for fixed-dose combinations.
Weaknesses include:
- Dolutegravir is a small molecule, so generic substitution is technically feasible.
- The active ingredient has been manufactured at large scale for years.
- Public-health licensing has created a mature global generic supply base.
- Abacavir-containing Triumeq faces clinical and commercial pressure independent of patent expiry.
- Treatment guidelines can move market share from single-agent dolutegravir toward newer long-acting or two-drug products.
What generic entry risks exist for dolutegravir?
The most likely U.S. generic sequence is:
- Entry of single-agent dolutegravir tablets after core compound protection expires.
- Price pressure on Tivicay and on branded regimen economics.
- Later competition against fixed-dose combinations, subject to separate patents and labeling.
- Increased substitution in Medicaid, government programs and managed-care formularies.
- International price compression in markets where generic TLD already dominates.
Generic entry would probably produce a sharper volume and net-price decline for Tivicay than for Dovato. Dovato may retain protection from combination-product patents and clinical positioning, while Triumeq is more exposed to therapeutic substitution because of abacavir use and the availability of two-drug alternatives.
Is there biosimilar risk for dolutegravir sodium?
There is no biosimilar risk because dolutegravir sodium is a chemically synthesized small molecule, not a biologic. The relevant threat is abbreviated generic competition under the ANDA pathway in the United States and equivalent small-molecule procedures in other jurisdictions.
The absence of biosimilar complexity makes manufacturing competition more predictable. Generic developers generally need to demonstrate pharmaceutical equivalence and bioequivalence rather than reproduce a biologic manufacturing process.
What licensing deals affect dolutegravir?
ViiV and the Medicines Patent Pool entered licensing arrangements to expand access to dolutegravir in lower-income countries. The agreements enabled selected manufacturers to supply generic dolutegravir, including pediatric formulations and TLD, in specified territories.
These licenses have two financial effects:
- They reduce branded pricing and direct sales opportunities in licensed markets.
- They expand patient access and preserve a large manufacturing ecosystem for the ingredient.
The access model also limits the commercial value of patent enforcement in many emerging markets. The United States, Western Europe, Japan and other higher-income markets generally remain outside the broadest generic-access licensing geography.
What litigation and settlement risks affect dolutegravir?
The principal litigation risk is an ANDA Paragraph IV challenge against listed Tivicay patents. The relevant outcomes are:
- Patent-owner enforcement, potentially producing a 30-month stay.
- A court finding of invalidity or non-infringement.
- A negotiated launch date before patent expiry.
- A settlement that permits an authorized generic or a delayed generic launch.
- A carve-out that excludes patented methods from the generic label.
Settlement economics will depend on the remaining patent term, the number of challengers, the strength of compound claims and the commercial value of Dovato or other successor products. A first-filer advantage can increase litigation pressure if several generic companies submit Paragraph IV certifications near the same time.
How does dolutegravir compare with competing HIV drugs?
| Drug or class |
Key commercial position |
Patent and market risk |
| Dolutegravir |
High-barrier integrase inhibitor used in Tivicay, Dovato and Triumeq |
Generic erosion in late 2020s; strong current global demand |
| Bictegravir |
Active ingredient in Biktarvy, Gilead’s leading single-tablet regimen |
Competes directly for treatment-naive and suppressed patients |
| Cabotegravir |
Long-acting integrase inhibitor in Cabenuva and Apretude |
Injectable administration creates manufacturing and administration barriers |
| Rilpivirine |
Component of Juluca and Cabenuva |
Narrower resistance and patient-selection profile |
| Elvitegravir |
Older integrase inhibitor associated with Genvoya and Stribild |
Greater legacy-product erosion |
| Doravirine |
NNRTI in Delstrigo and Pifeltro |
Competes in selected regimens but has less integrase-class momentum |
Biktarvy is the strongest branded competitor in many developed markets. Cabenuva offers a differentiated long-acting option and can reduce reliance on daily oral therapy. Dolutegravir retains an advantage in global public-health procurement because of cost, oral simplicity and extensive treatment-guideline support.
What is the financial trajectory for dolutegravir sodium?
The financial trajectory has three phases.
2013 to 2019: rapid adoption
Tivicay gained share as clinicians adopted integrase inhibitor-based treatment. Triumeq expanded the molecule into a complete single-tablet regimen. Revenue growth reflected clinical uptake, premium branded pricing and broad guideline adoption.
2020 to 2024: portfolio migration
Dovato added a two-drug growth platform while Triumeq matured. Tivicay remained commercially important, but growth shifted from the original single agent toward combination products. Public-sector demand for generic TLD expanded rapidly outside high-income markets.
Late 2020s onward: patent-driven erosion
Core patent expiry is likely to create the largest direct U.S. pricing event for Tivicay. The effect on ViiV’s total HIV revenue should be moderated by:
- Dovato and Juluca lifecycle management.
- Cabotegravir-based products.
- Delayed or staggered generic entry.
- Contracting and formulary strategies.
- Continued demand in markets with patent protection or limited generic competition.
The active ingredient should continue generating substantial global volume after branded exclusivity declines. Revenue will shift from premium branded sales toward high-volume, low-price generic supply.
What are the main commercial scenarios for generic launch?
| Scenario |
Timing |
Market effect |
| Delayed launch after full patent term |
Late 2020s or later |
Gradual erosion, with ViiV retaining more time for portfolio migration |
| Early settlement launch |
Before or near patent expiry |
Faster price decline but controlled market entry |
| Successful Paragraph IV invalidation |
Potentially before expiry |
Sharp U.S. price and share pressure |
| Narrow label carve-out |
Variable |
Generic competes for selected indications while branded combinations retain protection |
| Multiple simultaneous entrants |
Shortly after expiry |
Rapid discounting and limited generic profitability |
Key Takeaways
- Dolutegravir sodium is the foundation of Tivicay, Dovato, Triumeq, Juluca and global TLD regimens.
- ViiV’s branded dolutegravir portfolio remains a multibillion-pound commercial asset, although ingredient-level revenue is not separately reported.
- FDA NCE exclusivity ended in 2018; the more important U.S. barrier is the core patent estate extending into the late 2020s.
- Generic competition is already widespread in licensed and lower-income markets.
- The relevant competitive threat is generic substitution, not biosimilar entry.
- Dovato and newer long-acting products may reduce the impact of Tivicay patent expiry on ViiV’s total HIV revenue.
- Compound patents provide the strongest protection, while method-of-use and formulation patents are more vulnerable to label carve-outs and design-around strategies.
- Biktarvy is the leading branded oral competitor; Cabenuva is the main differentiated long-acting competitor.
FAQs
Is dolutegravir sodium the same as dolutegravir?
Dolutegravir sodium is the salt form used in commercial pharmaceutical products. Dolutegravir refers to the active moiety.
Can generic manufacturers sell TLD in the United States?
TLD is widely supplied in licensed international markets, but U.S. commercialization depends on FDA approval, applicable Orange Book patents and the scope of any licensing or settlement rights.
Which dolutegravir product is most exposed to generic competition?
Tivicay is the most direct target because it is a single-agent tablet. Fixed-dose combinations face separate formulation, combination and labeling considerations.
Does dolutegravir have pediatric patent protection?
Pediatric studies supported regulatory benefits and pediatric formulations, including dispersible tablets. Pediatric protection does not create a permanent separate exclusivity period for the active ingredient.
Will dolutegravir remain commercially important after patent expiry?
Yes. Branded revenue should decline in markets with generic substitution, but global patient volume is likely to remain high because dolutegravir is embedded in treatment guidelines and public-sector procurement.
References
-
Food and Drug Administration. (2013). FDA approves new drug to treat HIV infection. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2014). FDA approves Triumeq for HIV-1 infection. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2017). FDA approves Juluca for HIV-1 infection. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2019). FDA approves first two-drug complete regimen for HIV-1 infection. U.S. Department of Health and Human Services.
-
Medicines Patent Pool. (2014). Medicines Patent Pool and ViiV Healthcare sign licensing agreement for dolutegravir. Geneva, Switzerland.
-
U.S. Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for U.S. Patent No. 8,129,385 and related dolutegravir patents. Washington, DC.
-
ViiV Healthcare. (2024). Annual report and financial results. London, United Kingdom.
-
World Health Organization. (2021). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring. Geneva, Switzerland.
